- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Car accident.
Displaying page 1 of 1.
EudraCT Number: 2021-005192-39 | Sponsor Protocol Number: 202100663 | Start Date*: 2022-04-11 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell lymphoma who are treated with CD19-directed CAR T-cell therapy | ||
Medical condition: Patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of therapy who fulfill the eligibility criteria for CD19-directed CAR T-cell therapy according the Immune Effe... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005513-41 | Sponsor Protocol Number: TA799-012 | Start Date*: 2021-04-19 | |||||||||||
Sponsor Name:VectivBio AG | |||||||||||||
Full Title: An open-label extension trial to evaluate the long-term safety of apraglutide in short bowel syndrome | |||||||||||||
Medical condition: short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000954-67 | Sponsor Protocol Number: ATB200-07 | Start Date*: 2020-04-08 | |||||||||||
Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease | |||||||||||||
Medical condition: Adult Subjects With Late Onset Pompe Disease (LOPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) DK (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) SI (Trial now transitioned) AT (Completed) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001796-14 | Sponsor Protocol Number: CYTB323G12101 | Start Date*: 2023-03-20 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus (srSLE). | |||||||||||||
Medical condition: Systemic Lupus Erythematosus Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
